Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2 Completed 60 enrolled Alliance for Clinical Trials in Oncology National Cancer Institute (NCI) · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect). PURPOSE: This phase II trial is studying how well autologous peripheral stem cell transplant followed by donor peripheral stem cell transplant works in treating patients with multiple myeloma.

Timeline

Start: 2001-11
Primary completion: 2006-06
Completion: 2010-02

Publications

Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM Jr, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant. 2020 Aug;26(8):1414-1424. doi: 10.1016/j.bbmt.2020.03.028. Epub 2020 Apr 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD34+ cells	Unknown	2e+06 cells/kg	Intravenous
Subject	CD34+ cells	Unknown	8e+06 cells/kg	Intravenous
Subject	Cyclophosphamide	Other / unclassified	1000 mg/m2	Intravenous
Subject	Cyclophosphamide	Other / unclassified	4000 mg/m2	Intravenous
Subject	Fludarabine	Small molecule	30 mg/m2	Intravenous
Subject	Melphalan	Small molecule	200 mg/m2	Intravenous
Background	Methotrexate	Small molecule	5 mg/m2	Intravenous
Background	Tacrolimus	Small molecule	0.03 mg/kg	Oral
Background	filgrastim	Protein / enzyme biologic	5 ug/kg	Subcutaneous
Background	filgrastim	Protein / enzyme biologic	10 ug/kg	Subcutaneous

Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications